Home / Health / Ivermectin: The FDA warns against using the drug to treat or prevent Covid-19.

Ivermectin: The FDA warns against using the drug to treat or prevent Covid-19.

There appears to be growing interest in a drug called ivermectin to treat humans infected with COVID-19. Ivermectin is often used in the United States to treat or prevent animal parasites. Medical and Was hospitalized after self-treatment with ivermectin intended for horses. “The agency’s announcement said on Friday.

The announcement states that the FDA has not approved ivermectin to treat or prevent Covid-19 in humans, and the drug is not an antiviral drug.

Everything old is new again: replacing drugs to treat COVID-1[ads1]9

“Taking high doses of this drug is dangerous and potentially serious,” the announcement said, noting that even ivermectin levels approved for other uses can interact with other drugs such as thinner. blood

You can also overdose with ivermectin, which can cause nausea, vomiting, diarrhea, hypotension. (Low blood pressure), allergic reactions (itching and hives), dizziness, ataxia (problems with balance), seizures, coma, and even death.

The announcement comes just a day after new research published in the medical journal JAMA found that ivermectin doesn’t appear to be. It’s time for improvement in patients with Covid-19 infection.
In January, the National Institutes of Health’s therapeutic committee said there was not enough information to recommend or oppose the drug to treat COVID-19 patients.
The latest about the coronavirus and vaccine epidemic
The drug is a low-cost drug with anti-inflammatory properties and appears to stop the virus from replicating in laboratory studies. But more research is needed to determine how the drug might be effective against Covid-19 in real life.

In a JAMA study in Cali, Colombia, nearly 500 adults with mild disease who had the condition for 7 days volunteered to help test the drug. The trial, known as a randomized, double-blind controlled trial, is the gold standard of trials.

Half of the subjects received the drug for five days, the other half received a placebo and standard care. Patients are enrolled in the trial between July 2020 and November 2020 and their doctors will follow up with them until December.

At the end of the trial, nearly the same number of adverse events were reported, most of which were headaches in both subjects. The patients who received the drug said their symptoms decreased by 10 days; for the placebo group, it was 12 days.

Two days is not a “significant” improvement.

“These findings do not support the use of ivermectin to treat mild COVID-19,” said Colombian researchers. Further studies on whether larger trials may be needed to better understand whether ivermectin provides any other benefit to patients with Covid-19 infection. In this case, the study focuses on symptoms and diseases that are not. severe

Source link